Table 3.
Summary of nine studies comparing the RECIST and PERCIST
| Study | Tumor type | No. of pts | Treatment | Comparison | Discordant rate, % | Details of discordance |
|---|---|---|---|---|---|---|
| RECIST→ EORTC | ||||||
| Thacker et al. (2012) [15] | Basal cell carcinoma | 14 | Targeted agent (vismodegib) | RECIST 1.0 vs. PERCIST | 50 (7/14) | 2 PR→1 CMR, 1 SMD |
| 4 SD→4 PMR | ||||||
| 1 PD→1 SMD | ||||||
| Aras et al. (2016) [20] | Colorectal cancer | 20 | Palliative chemotherapy | RECIST 1.1 vs. PERCIST | 18.3 (11/60) | 4 PR→3 CMR, 1 SMD |
| Lung cancer | 16 | 7 SD→7 PMR | ||||
| Stomach cancer | 12 | |||||
| Head & neck cancer | 6 | |||||
| Breast cancer | 6 | |||||
| Shang et al. (2016) [21] | Non-small cell lung cancer | 35 | Chemotherapy | RECIST 1.1 vs. PERCIST | 62.9 (22/35) | 18 SD→14 PMR, 4 PMD |
| 4 PD→4 SMD | ||||||
| Ding et al. (2014) [22] | Non-small cell lung cancer | 44 | Palliative chemotherapy | RECIST 1.1 vs. PERCIST | 34.1 (15/44) | 6 PR→4 CMR, 2 SMD |
| 9 SD→1 CMR, 7 PMR, 1 PMD | ||||||
| Skougaard et al. (2014) [23] | Colorectal cancer | 61 | Palliative chemotherapy | RECIST 1.0 vs. PERCIST | 54.1 (33/61) | 1 PR→1 SMD |
| 24 SD→20 PMR, 4 PMD | ||||||
| 8 PD→4 PMR, 4 SMD | ||||||
| Yanagawa et al. (2012) [24]a | Esophageal cancer | 46 | Neoadjuvant chemotherapy | RECIST 1.1 vs. PERCIST | 56.5 (26/46) | 13 PR→13 CMR |
| 13 SD→3 CMR, 10 PMR | ||||||
| Agrawal et al. (2014) [25] | Breast cancer | 22 | Metronomic palliative hemotherapy | RECIST 1.1 vs. PERCIST | 20.6 (9/43) | 8 SD→1 CMR, 1 PMR, 6 PMD |
| PNET | 5 | 1 PD→1 CMR | ||||
| Head & neck cancer | 4 | |||||
| Sarcoma | 3 | |||||
| NHL | 2 | |||||
| Esophageal cancer | 2 | |||||
| Others | 5 | |||||
| Riedl et al. (2017) [26] | Breast cancer | 65 | Chemotherapy, targeted therapy, hormonal therapy | RECIST 1.1 vs. PERCIST | 52.3 (34/65) | 10 PR→10 CMR |
| 20 SD→6 CMR, 8 PMR, 6 PMD | ||||||
| 4 PD→3 CMR, 1 SMD | ||||||
| Bang et al. (2017) [27] | Colorectal cancer | 39 | Targeted therapy (regorafenib) | RECIST 1.1 vs. PERCIST | 61.5 (24/39) | 1 PR→1 SMD |
| 17 SD→14 PMR, 3 PMD | ||||||
| 6 PD→3 PMR, 3 SMD | ||||||
| Summary | Colorectal cancer | 120 | RECIST vs. PERCIST | 44.5 (181/407) | 37 PR→31 CMR, 6 SMD | |
| Lung cancer | 95 | 120 SD→11 CMR, 85 PMR, 24 PMD | ||||
| Breast cancer | 93 | 24 PD→4 CMR, 7 PMR, 13 SMD | ||||
| Esophageal cancer | 48 | |||||
| Basal cell carcinoma | 14 | |||||
| Stomach cancer | 12 | |||||
| Head & neck cancer | 10 | |||||
| Others | 16 |
RECIST, Response Evaluation Criteria in Solid Tumors; PERCIST, Positron Emission Tomography Response Criteria in Solid umors; pts, patients; PR, partial response; CMR, complete metabolic response; SMD, stable metabolic disease; SD, stable disease; PMR, partial metabolic response; PD, progressive disease; PMD, progressive metabolic disease; PNET, primitive neuroectodermal tumor; NHL, non-Hodgkin’s lymphoma.
a
Five patients were excluded from the final analysis because their disease was not classifiable according to the RECIST 1.1.